Introduction
Hydroxymethylglutaryl-CoA reductase (HMG-CoA reductase) is a key enzyme in the mevalonate pathway, from which thousands of vital molecules are derived including cholesterol, which is involved in membrane structure and steroid production, ubiquinone and heme-␣, which are associated with the mitochondrial respiratory chain, and dolichol, which is required for glycoprotein synthesis. 1 Recent studies have identified over 40 proteins with mevalonate-derived prenyl groups attached post-translationally. 2 These proteins include p21 ras proteins, lamin A and lamin B which may play essential roles in the progression through the cell cycle [3] [4] [5] as well as several M r 20 000-25 000 proteins which may regulate critical functions involved in cellular growth control. 2 Thus, physiological regulation of HMG-CoA reductase is strongly believed to be essential for the maintenance of cellular homeostasis.
A number of highly selective inhibitors of the mevalonate pathway have been developed to decrease elevated plasma cholesterol. 6 These agents have also been considered as potential antitumor agents because of their ability to inhibit the growth of cells dependent on de novo synthesis of cholesterol. 7 Lovastatin, one of the specific competitive inhibitors of HMG-CoA reductase, has been demonstrated to be a strong inhibitor of neoplastic cell proliferation and a powerful inducer of apoptosis and cell cycle alterations (G 0 /G 1 cell cycle phase block) in various tumor cell lines. [8] [9] [10] [11] Moreover, lovastatin has been reported to preferentially target multidrugresistant neoplastic cells in myeloma, 12 breast carcinoma 13 and neuroblastoma 14 compared with their parental drug-sensitive cells in vitro. As for leukemia cell lines, a human multidrug-resistant myeloid leukemia cell line, HL-60/VCR, was recently shown to be equally sensitive to lovastatin, 15 suggesting that the increased sensitivity to lovastatin observed by some investigators was not a general phenomenon for drugresistant neoplastic cells expressing P-glycoprotein.
The present study was therefore undertaken to further address the relationships between Pgp expression and sensitivity to lovastatin in other multidrug-resistant myeloid leukemia cell lines.
Materials and methods

Reagents
Lovastatin was generously provided by Merck Research Laboratories, Rahway, NJ, USA. To convert the inactive form of lovastatin to the active lactone form, the drug was dissolved in ethanol, heated at 50°C in 0.1 N NaOH, neutralized with HCl, and stored unfiltered as a 4 mg/ml stock solution at 4°C for 2 months. DL-mevalonic acid lactone, MTT (3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium-bromide), and propidium iodide were obtained from Sigma-Aldrich, Tokyo, Japan.
Cell lines
A human chronic myelogeneous leukemia cell line, K-562, was obtained from the Japanese Cancer Research Resources Bank and its adriamycin-resistant subline, K-562/ADR, was kindly provided by Dr T Tsuruo (University of Tokyo, Tokyo, Japan). 16 A human myelomonocytic leukemia cell line, NOMO-1, and its adriamycin-resistant subline, NOMO-1/ADR, were kindly provided by Dr M Ogura (Aichi Cancer Center, Nagoya, Japan) and Dr M Tanimoto (Nagoya University, Nagoya, Japan). 17 A human promyelocytic leukemia cell line, NB4, was kindly provided by Dr M Lanotte (Hospital Saint-Louis, Paris, France) 18 and its retinoic acid-resistant subline, NB4/RA, was kindly provided by Dr K Kitamura (Nagoya University).
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NB4/MDR and NB4/RA/MDR sublines were established by transduction of NB4 and NB4/RA with HaMDR retrovirus and subsequent selection of the transduced cells with 4 ng/ml vincristine as reported previously. 20 All cell lines were cultured in RPMI 1640, supplemented with 1% penicillin/streptomycin, 1 mmol/l L-glutamine and 10% heatinactivated fetal calf serum (FCS, Gibco BRL, Auckland, New Zealand), at 37°C in 5% CO 2 humidified atmosphere. Adriamycin (400 nM) was added every 2 weeks to the culture medium of K-562/ADR and NOMO/ADR, and vincristine (4 ng/ml) was added to the complete medium of NB4/MDR and NB4/RA/MDR cell lines. Cells were grown for 7 days in the absence of the drugs prior to use in specific experiments.
Flow cytometric analysis of apoptosis and P-glycoprotein
Apoptosis was identified and quantified by flow cytometry with propidium iodide (PI) staining. 21 P-glycoprotein was analyzed by a flow cytometric assay using biotinylated MRK16 mAb (b-MRK16) (Kyowa, Sunto-Gun, Japan) and streptavidin-RED670 conjugate (SA-RED 670) (Gibco BRL, Gaithersburg, MD, USA) as described previously. 22 Briefly, cells were first incubated in 0.5% Polyglobin N (Miles, West Haven, NJ, USA) at room temperature to block non-specific binding, and then incubated with either 1 g of b-MRK16 or 1 g subclassmatched biotinylated IgG2a mAb (negative control) for 30 min on ice. After washing twice in PBS, the cell pellet was resuspended and incubated with 1 g of SA-RED670 conjugate for 30 min on ice. The cells were then washed and resuspended in PBS containing 2% of FCS for flow cytometric assay.
DNA fragmentation assay
Apoptosis was further confirmed by the detection of DNA fragmentation described previously. 23 
Cell viability
Cell viability was measured by MTT assay as described by Mosmann 24 with slight modification. After incubation for 48 h, 10 l (5 mg/ml) MTT was added to each well, and plates were incubated at 37°C for 4 h. Acid-isopropanol (0.04 N HCl in isopropanol) (100 l) was added to each well and mixed by pipetting to dissolve the reduced MTT formazans, and relative cell viability was measured by ELISA reader at dual wavelength of 550 and 600 nm with consequent processing of the data using Delta Soft 4.0B software.
mRNA analysis
Total RNA was isolated with Tri-Reagent (MRC, Cincinnati, OH, USA). mRNA expression was assessed by reverse transcriptase PCR (RT-PCR). For the RT reaction, RNA (10 g) was primed with random hexamer and reverse transcribed with 2.5 l Superscript MMLV reverse transcriptase (Gibco BRL). The cDNA generated was amplified by using primers for GAPDH (glyceraldehyde-phosphate-dehydrogenase) described in Ref. 25 ; set primers for HMG-CoA reductase reported in Ref. 14 and primers for MDR-1 described in Ref. 26 . PCR mixture (50 l) contained 1 l of the RT reaction, 20 pmol of each dNTP (0.2 mmol/l) and 2.5 U of GoldAmplyTag polymerase (Perkin Elmer, Branchburg, NJ, USA). The PCR reaction protocol for GAPDH and MDR-1 was as follows: 94°C for 1 min, 55°C for 1 min and 72°C for 1.5 min; for HMG-CoA reductase: 94°C for 1.5 min, 60°C for 1.5 min and 72°C for 2 min for 30 cycles. The expected PCR products: 898 bp (GAPDH), 243 bp (MDR) and 525 bp (HMG-CoA reductase), were size fractionated on to agarose gel and stained with ethidium bromide.
Leukemia
Results
MDR-1 gene expression and membrane Pgp distribution
Since drug-resistant cell lines used have come from different sources, and methods by which they become drug resistant are variable, all cell lines were examined for MDR-1 gene expression and Pgp distribution before starting experiments with lovastatin. As shown in Figure 1 , K-562/ADR, NOMO/ADR, NB4/MDR and NB/RA/MDR cells highly expressed mRNA of MDR-1 gene, while their parental counterpart showed low or undetectable levels of the gene. The membrane distribution of Pgp in resistant sublines varied from 57.2% in NB4/MDR up to 99.6% in K-562/ADR (Figure 2 ), whereas membrane Pgp was not detected in any of the parental drug-sensitive cells (data not shown).
The viability and apoptosis of leukemia cell lines in response to lovastatin
The cytotoxic effects of lovastatin on eight leukemia cell lines were evaluated by MTT assay. Cells were treated with lovastatin (0.1 to 100 M) for 48 h. The growth of all cell lines was inhibited by lovastatin in a time-and dose-dependent manner. Simultaneous addition of mevalonate (300 M) completely prevented the cell growth inhibition, indicating that lovastatin specifically depleted mevalonate in the cells. The concentrations of lovastatin to induce a 50% decline in MTT activity (MTT 50 ) are shown in Figure 3 . NB4 cells were apparently the most sensitive to lovastatin, and a significant decrease of MTT was observed at a concentration as low as 2 M, which was around 40-and 10-fold lower than those for K-562 and NOMO-1 cells, respectively (P Ͻ 0.01). NB4/RA was significantly more resistant to lovastatin than NB4 cells. Multidrugresistant sublines showed two-to 2.5-fold lower MTT 50 values than those of their parental cell lines except for NB4/MDR, the parental cell line of which already showed very high sensitivity to lovastatin. When DNA from lovastatin-treated cells was analyzed on agarose gel, typical apoptotic DNA laddering was observed (Figure 4) . Flow cytometric analysis of lovastatin-treated cell lines typically showed pre-G1 peaks due to nuclear fragmentation. As shown in Figure 5 , lovastatin induced accumulation of pre-G1 peaks to a greater extent in
Figure 1
Expression of MDR-1 mRNA. Total RNA was purified from leukemia cell lines and subjected to semiquantitative RT-PCR analysis with oligonucleotide primers specific for MDR-1. After 24 cycles (shown to be at the linear phase of amplification), PCR products were electrophoresed on to a 2% agarose gel and stained with ethidium bromide. multidrug-resistant sublines than parental cell lines. The result was consistent with the findings of the MTT assay. Thus, multidrug-resistant sublines were for the most part more sensitive to lovastatin than their parental cell lines in terms of cytotoxicity and apoptosis.
Modulation of HMG-CoA reductase by lovastatin in leukemia cell lines
The effects of lovastatin on HMG-CoA reductase mRNA levels were next evaluated by semiquantitative RT-PCR analysis. DNA fragmentation in leukemia cell lines following lovastatin treatment for 48 h. The lanes in the gel were loaded with 5 l (1 g) of the genomic DNA.
Before the treatment with lovastatin, all cell lines expressed detectable levels of HMG-CoA reductase mRNA, but multidrug-resistant sublines displayed significantly higher levels of mRNA than their parental cell lines except for NB4/MDR ( Figure 6 ). Following the lovastatin treatment, HMG-CoA reductase mRNA levels were increased by more than two-fold in all parental cell lines, whereas in multidrug-resistant sublines, which showed higher sensitivity to lovastatin and higher mRNA expression in basal conditions, the HMG-CoA reductase mRNA levels were not further up-regulated except for NB4/MDR, in which the low pre-treatment mRNA was increased to a similar extent as in its parental NB4 cell line by the lovastatin treatment ( Figure 6 ).
Discussion
In this study we investigated the sensitivity to lovastatin of various leukemia cell lines and their MDR Pgp-expressing sublines in terms of growth inhibition and apoptosis. We used two sublines which had been selected as resistant clones by step-wise administration of adriamycin (K-562/ADR and NOMO-1/ADR) and two sublines which had been transduced with a MDR-1 gene vector (NB4/MDR and NB4/RA/MDR). Neither MDR-related protein nor lung-resistant protein was detectable in the above drug resistant cell lines. 27 The order
Leukemia of sensitivity to lovastatin of parental Pgp-negative leukemia cells was NB4ϾNOMO-1ϾNB4/RAϾK562. The human acute promyelocytic leukemia cell line, NB4, was very sensitive to lovastatin, with MTT 50 of as low as 2 M. Of note, in the phase I study of lovastatin as an anti-cancer drug, doses up to 25 mg/kg/day were well tolerated and yielded peak serum levels in the range of 0.1 to 3.95 M. 28 Besides, the effects of lovastatin on normal marrow progenitors and hematopoiesis were reportedly negligible. 29, 30 Therefore, our data further strengthen the idea that lovastatin might have a potential therapeutic role in the treatment of acute promyelocytic leukemia. 11 In contrast, the human chronic myelogeneous leukemia cell line, K562, displayed low sensitivity to lovastatin. The susceptibility of cells to cytotoxic and apoptotic signals appears to be regulated by complex cellular factors involved in the cell death pathway. 31 Many apoptosis-suppressing pro- teins have been implicated in relative resistance and susceptibility to antitumor treatment. For instance, Bcl-X L and BCR-ABL 32, 33 are shown to be highly expressed in K-562 cells. 34, 35 Moreover, a strong association between Bcl-X L and Pgp expression has been found in leukemic cell lines. 36, 37 In view of the wide expression of apoptosis-protecting molecules in K-562 cells, the finding that K-562 cells were most resistant to lovastatin in our study is not surprising.
The mechanisms whereby lovastatin suppresses cell growth and triggers apoptosis are unclear at present, although either ras-dependent or ras-independent pathways have been discussed. 38 Moreover, the mechanism by which some multi-drug-resistant neoplastic cells develop preferential sensitivity to lovastatin also remains to be elucidated. It has been shown that neoplastic cells require high level of cholesterol biosynthesis. 39 Pgp plays a role in cholesterol biosynthesis by transporting of sterol precursors from plasma membrane to endoplasmic reticulum. 40, 41 Thus, it has been speculated that Pgp may down-regulate de novo cholesterol synthesis by a feedback mechanism via the mevalonate pathway. 15 Of note, cholesterol level was found to increase by as much as 50% in some multidrug resistant cells in comparison with their parental cells. 42, 43 Present study showed that Pgp-expressing leukemia cell lines K-562/ADR, NOMO-1/ADR and NB4/RA/MDR were more sensitive to lovastatin than their parental cell lines in terms of inhibition of proliferation and induction of apoptosis. However, despite the high expression of MDR-1 mRNA and Pgp on membrane, the MDR-1 genetransduced variant of NB4, NB4/MDR, was not more sensitive to lovastatin, showing equal sensitivity to lovastatin as their parental cells. The discrepancy between NB4/MDR and NB4/RA/MDR could probably be explained by the different HMG-CoA reductase mRNA levels. We found that HMG-CoA reductase transcript levels were significantly different between parental cells and multidrug-resistant sublines except for NB4/MDR. Treatment with lovastatin did not lead to further significant increase in HMG-CoA reductase mRNA in drug resistant variants, but did in drug sensitive parental cells, suggesting some inability of drug resistant counterparts to compensate for loss of enzyme function. The result that NB4 and NB4/MDR cells showed equal sensitivity to lovastatin can probably be explained by the equal expression of HMG-CoA reductase in these two cell lines ( Figure 6 ) and thus by the equal compensatory resources to overcome lovastatininduced mevalonate blockade. Otherwise the equal sensitivity of NB4 and NB4/MDR cells could suggest that other mechanisms besides Pgp and the transcript level of HMG-CoA reductase may be involved in the complexity of the sensitivity phenomenon to lovastatin of NB4 cell line which was already very sensitive to lovastatin before MDR-1 transfection. Interestingly, that the RA-resistant subline of NB4, NB4/RA (Pgp negative), was significantly less sensitive to lovastatin than NB4 cells, supports recent findings that retinoic acid responsiveness is associated with increased sensitivity to lovastatin. 11, 14 On the other hand, NB4/RA cells when made MDR resistant show a significantly higher expression of HMG-CoA reductase than their parental counterparts and undergo induction of profound apoptosis. HMG-CoA reductase is regulated in a complex manner, 1 further investigations are required to analyze the translational processes and activity of HMG-CoA reductase in multidrug-resistant and drug sensitive leukemia cells, and to elucidate the mechanisms underlying differential cytotoxic responses to lovastatin.
The present study indicates that Pgp plays a certain regulatory role in lovastatin sensitivity of neoplastic cells due to a connection between multidrug resistance and regulation of mevalonate pathway, and suggest the clinical possibility that drug resistant leukemias would be susceptible to treatment with lovastatin.
